Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02135445 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT02135445: Completed Phase 2 study, sponsored by Millennium Pharmaceuticals.
NCT02135445 is a Phase 2 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 103 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02135445, a Phase 2 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of TAK-385 for achieving and maintaining testosterone suppression.
Primary Outcome
Castration rate is defined as the observed percentage of participants who have testosterone concentrations less than (\<) 50 nanogram per deciliter (ng/dL) (1.73 nanomole per liter \[nmol/L\]) at all scheduled visits.
Interventions
- DRUG Degarelix
- DRUG TAK-385
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
What the finished NCT02135445 record still lists
NCT02135445 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 2 interventions - of which Degarelix is the first listed.
NCT02135445 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02135445 about?
NCT02135445 is a clinical study titled "Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer". The purpose of this study is to evaluate the efficacy of TAK-385 for achieving and maintaining testosterone suppression.
What is the current status of trial NCT02135445?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2014-06. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02135445?
The interventions under investigation include: Degarelix (DRUG), TAK-385 (DRUG).
Who is sponsoring clinical trial NCT02135445?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02135445's enrollment target sits among peer trials
103 664th of 2000 higher than 1,333 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia